18 news items
Mizuho Maintains Buy on Immunocore Hldgs, Lowers Price Target to $88
IMCR
13 May 24
Mizuho analyst Graig Suvannavejh maintains Immunocore Hldgs (NASDAQ:IMCR) with a Buy and lowers the price target from $90 to $88.
Canaccord Genuity Maintains Hold on Immunocore Hldgs, Raises Price Target to $67
IMCR
9 May 24
Canaccord Genuity analyst Bill Maughan maintains Immunocore Hldgs (NASDAQ:IMCR) with a Hold and raises the price target from $63 to $67.
HC Wainwright & Co. Maintains Buy on Immunocore Hldgs, Raises Price Target to $100
IMCR
9 May 24
HC Wainwright & Co. analyst Patrick Trucchio maintains Immunocore Hldgs (NASDAQ:IMCR) with a Buy and raises the price target from $90 to $100.
Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price Target
IMCR
9 May 24
Needham analyst Gil Blum reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $81 price target.
Where Immunocore Hldgs Stands With Analysts
IMCR
29 Apr 24
0
Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.4, a high
gcpmy50yxjp1n67v3dji4b1viibmgl1czw78xz8q1s4lfoiv1htbk
IMCR
29 Apr 24
Leerink Partners analyst Jonathan Chang initiates coverage on Immunocore Hldgs (NASDAQ:IMCR) with a Outperform rating and announces Price Target of $74.
8gw2k j3u
IMCR
23 Apr 24
Guggenheim analyst Michael Schmidt reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $92 price target.
paaac877bq
IMCR
11 Apr 24
0
Analysts have recently evaluated Immunocore Hldgs and provided 12-month price targets. The average
svu7nl
IMCR
11 Apr 24
Needham analyst Gil Blum reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $81 price target.
scm kypedic3xk7v50m
IMCR
21 Mar 24
JP Morgan analyst Jessica Fye maintains Immunocore Hldgs (NASDAQ:IMCR) with a Overweight and raises the price target from $60 to $70.
r9t7dczmwa9d tqkeaa
IMCR
5 Mar 24
a major barrier to therapeutic targeting Presenting author: Zoe WallaceSession: HIV immunotherapy
zvvx4d0vb37tq5tmqyxuvnlpf8s4wz2zjmw1a3pgigonc3eflz5stnxr
IMCR
5 Mar 24
Mizuho analyst Graig Suvannavejh maintains Immunocore Hldgs (NASDAQ:IMCR) with a Buy and raises the price target from $86 to $90.
51rqi7ng9y2ni1 liurp
IMCR
29 Feb 24
0
Providing deeper insights, analysts have established 12-month price targets, indicating an average target
o7vs82qhn0dqkn8v79d7y4z7445k8zh9aq
IMCR
29 Feb 24
Oppenheimer analyst Justin Kim reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Outperform and raises the price target from $85 to $87.
qg28ju7v55l75irt97bv3n4q0xe6fvn26conmm 83j7c2uw
IMCR
29 Feb 24
Canaccord Genuity analyst Bill Maughan maintains Immunocore Hldgs (NASDAQ:IMCR) with a Hold and raises the price target from $60 to $63.
ehjsff 0c9
IMCR
29 Feb 24
Needham analyst Gil Blum reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $81 price target.
nz4dvzcgmk49tv1whsw p5m5cmx72dy3nu2sem1gkenf5
BMY
IMCR
28 Feb 24
targeting PIWIL1, to begin Phase 1 trial in colorectal and other gastrointestinal cancers in 2H 2024 Data from IMC-M113V
f94yspy k79m
BMY
IMCR
22 Feb 24
The company will investigate Immunocore's ImmTAC bispecific TCR (T cell receptor) candidate targeting PRAME HLA-A02, IMC-F106C, in combination
- Prev
- 1
- Next